Universität zu Köln

Hohberg, Melanie, Eschner, Wolfgang, Schmidt, Matthias, Dietlein, Markus, Kobe, Carsten, Fischer, Thomas, Drzezga, Alexander and Wild, Markus (2016). Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [Lu-177]DKFZ-PSMA-617. Mol. Imaging. Biol., 18 (3). S. 437 - 446. NEW YORK: SPRINGER. ISSN 1860-2002

Full text not available from this repository.

Abstract

Calculating the absorbed dose is important for the determination of risk and therapeutic benefit of internal radiation therapy. The aim of this study was to perform image-based absorbed dose calculation for critical organs during the first cycle of [Lu-177]DKFZ-PSMA-617 therapy in a small cohort of patients with metastatic prostate cancer. Nine patients with a history of prostate cancer documented by histopathology and radiologic evidence of metastatic diseases underwent radioligand therapy with [Lu-177]DKFZ-PSMA-617. Conjugated planar whole-body scintigraphies acquired at 0.5, 24, 48, 72, and 168 h post-injection were analyzed by regions of interest, and time-activity curves were generated for various organs. Cumulated activities and residence times were calculated by bi-exponential fit of the time-activity curves. Mean absorbed doses were finally estimated using OLINDA/EXM1.1 (TM). Additionally, the uncertainty when omitting the last measurement (168 h p.i.) was studied. The following mean absorbed doses were calculated: 2.82 mGy/MBq for the lacrimal glands, 0.72 mGy/MBq for the salivary glands, 0.53 mGy/MBq for the kidneys, and 0.42 mGy/MBq for the nasal mucous membrane. Omitting the last measurement resulted in a mean deviation of 10 to 25 % for absorbed dose values as compared to the ones received by analyzing all measurements. Absorbed organ doses of [Lu-177]DKFZ-PSMA-617 therapy are not likely to be critical for kidneys, salivary glands, and the nasal mucous membrane. The lacrimal glands may represent the dose-limiting organs. Whole-body scintigraphy appears sufficient for dose estimation, but late measurements are mandatory, if accurate dose calculation is required.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hohberg, Melanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Eschner, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Wild, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-274110
DOI:	10.1007/s11307-016-0942-0
Journal or Publication Title:	Mol. Imaging. Biol.
Volume:	18
Number:	3
Page Range:	S. 437 - 446
Date:	2016
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1860-2002
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MEMBRANE ANTIGEN; PSMA INHIBITOR; DOSIMETRY; EXPRESSION; LIGAND; PET Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27411